BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211101
DTEND;VALUE=DATE:20211104
DTSTAMP:20260515T231521
CREATED:20210720T100504Z
LAST-MODIFIED:20210720T100504Z
UID:31015-1635724800-1635983999@www.pharmajournalist.com
SUMMARY:5th Antifibrotic Drug Development Summit - AFDD
DESCRIPTION:The 5th Antifibrotic Drug Development Summit will provide a unique opportunity to gain cross-discipline actionable insights into how the latest scientific research is being applied to fibrosis pipeline progress. Network with industry pioneers in hot areas of drug development\, specifically IPF\, NASH\, scleroderma\, IBD\, ILD\, CKD\, and more to apply disease-specific lessons agnostically\, and understand how the industry can achieve the crowning glory of pan-fibrosis antifibrotic drugs. \nUnmissable Highlights for 2021:  \n\nJoin the active discussion surrounding redefining approvable clinical endpoints with the FDA to enhance opportunities for creative clinical trial design and drive your clinical development\nEngage with early initiatives to establish clinical development programs in IBD-associated fibrosis with Cleveland Clinic to kickstart your intestinal fibrosis pipeline as this grows in interest for biopharma\nInvestigate the buzz around reprogramming epithelial cells to promote tissue repair in fibrotic disorders with Genentech to understand new strategies for regenerative medicine and overcome mechanistic bottlenecks\nGain vital insights from Pfizer on how the industry can revolutionize the translatability of current disease models and collaboratively guide the creation of technologies that can better mimic human physiology\nEmbrace more successful clinical trial design with an enhanced focus on patient-reported outcomes with Novartis to identify precision medicine approaches\, promote patient engagement\, and discuss regulatory barriers to novel endpoints\n\nHear from 35+ industry heavyweights including Genentech\, AstraZeneca\, FDA\, GSK\, Boehringer Ingelheim\, Pfizer\, Takeda\, and more to understand transformative mechanistic strategies for promoting tissue regeneration and repair\, discover more robust predictive models to improve translatability; and assess emerging non-invasive biomarkers that identify early signs of efficacy and drive successful clinical trials. \nTo know more visit: https://ter.li/afddpjel
URL:https://www.pharmajournalist.com/event/5th-antifibrotic-drug-development-summit-afdd/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211102
DTEND;VALUE=DATE:20211105
DTSTAMP:20260515T231521
CREATED:20210823T081823Z
LAST-MODIFIED:20210823T081930Z
UID:31388-1635811200-1636070399@www.pharmajournalist.com
SUMMARY:Gastrointestinal Cancer Drug Development Summit
DESCRIPTION:The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies\, ADCs\, and precision oncology to address the large unmet clinical need in GI cancers. \n**This meeting is free-to-attend for drug developers\, research institutions\, and not-for-profit organizations**. \nRegister free to attend here: https://ter.li/t83wdr    \nThis industry-dedicated meeting offers a comprehensive insight into developing optimal clinical programs for targeted\, immune\, and ADC therapies in these solid tumors. Join us and our 39+ expert speaker faculty as we navigate cancer heterogeneity and develop biomarker-driven enrichment strategies to direct better treatments to specific patient subsets and invest in rationale therapeutic combination approaches for this vastly unmet clinical need. \nWhether your group is targeting microsatellite instable (MSI) and stable (MSS) CRC\, a rare GI malignancy or treatment-resistant HCC\, this unique forum is your opportunity to establish clinical collaborations\, plan new combinatorial studies and assess how a future drug candidate can change the clinical landscape. \nExplore the full conference guide here: https://ter.li/9m9m8u \n**A “drug developer” or “researcher” must have a pipeline candidate and/or work for an academic institution\, and must not provide solutions or services for a fee to any other company. All bookings under the drug developer/researcher category are subject to organizer approval.
URL:https://www.pharmajournalist.com/event/gastrointestinal-cancer-drug-development-summit/
LOCATION:Digital Event | EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR